Physician profile
Jonathan Mark Morena
NPI 1245734474
$3,303.81
in general payments reported to CMS, 2019-2025
9 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $113 · 2021: $70.41 · 2022: $362 · 2023: $249 · 2024: $999 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,693 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $688 · Food and Beverage: $335 · Travel and Lodging: $43.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,692.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $687.50 |
| Food and Beverage | $334.88 |
| Travel and Lodging | $43.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $887.50 | 2024 | |
| Amgen INC. | $704.02 | 2025 | Uplizna |
| Ucb, INC. | $630.00 | 2025 | Rystiggo |
| Argenx US, INC. | $397.30 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $244.18 | 2022 | |
| Allergan, INC. | $183.90 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Kyowa Kirin, INC. | $81.91 | 2023 | Nourianz |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Morena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.